




OUTBACK

A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone

Study Chair: A/Prof Linda Mileskin




Schema





Accrual Chart





Current status

	ANZGOG		NRG				
<i>Country</i>	Australia	New Zealand	USA	Canada	China	Saudi Arabia	Singapore
<i>Sites Open</i>	12	3	282	6	1	1	1
<i>Accrual</i>	135	18	647	23	4	5	1



196 QA reports finalised

- 49 major deviations
- 109 minor deviations
- 26 patients had multiple deviations



- Amendment to increase sample size from 780 to 900 now approved
- On track to complete recruitment in 1st quarter of 2017